You are here

SPIRIT 2 - Dasatinib continuation at end of trial

Following the excellent patients conference at Hammersmith Hospital on Saturday I thought I would update on a conversation I had with Professor Steve O'Brien who runs the SPIRIT 2 trial. The trial is now coming towards its close after 5 years and there has been understandably some worry as Dasatinib is not NHS funded as to its availability afterwards.

Professor O'Brien at one of break out sessions told me the following; Dasatinib will continue to be available to patients on that have been on the trial on a long term basis, and so any patients that have been involved in the trial will still have access to it. Imatinib fully funded already and so there no issue with it.